fbpx

Trimoksazol®

Sulfamethoxazole + trimethoprim

Tablets (400 mg+80 mg) 
Syrup (200 mg+40 mg)/5 ml

ATC J01E E01

Prescription-only medicine

Medicines reimbursed by the Health Insurance Fund

POSOLOGY AND METHOD OF ADMINISTRATION


Treatment should be continued until the patient has been symptom-free for 2 days; the majority will require treatment for at least 5 days. If clinical improvement is not evident after 7 days of therapy, the patient should be reassessed.

It may be preferable to take Trimoksazol® with food or drink to minimise the possibility of gastrointestinal disturbances.


Adults and children above 12 years: 2 tablets in the morning and 2 tablets in the evening

Children from 6 to 12 years: 5 ml syrup in the morning and 5 ml syrup in the evening

Children from 6 months to 5 years: 5 ml syrup in the morning and 5 ml syrup in the evening

Children from 6 weeks to 5 months: 2.5 ml syrup in the morning and 2.5 ml syrup in the evening


Medicine’s information on this web page is only a short description of its characteristics. Do not take them as recommendations for self-treatment of your health condition.

You must inform your physician and pharmacist and follow their recommendations before you use the medicine for treatment. Always read carefully the patient information leaflet.

COMPOSITION

Each tablet contains 400 mg sulfamethoxazole and 80 mg trimethoprim, excipients.
5ml syrup contains 200 mg sulfamethoxazole and 40 mg trimethoprim, excipients.

THERAPEUTIC INDICATIONS

Trimoksazol® should only be used where, in the judgment of the physician, the benefits of treatment outweigh any possible risks; consideration should be given to the use of a single effective antibacterial agent. The in vitro susceptibility of bacteria to antibiotics varies geographically and with time; the local situation should always be considered when selecting antibiotic therapy.
1) Treatment and prophylaxis (primary and secondary) of Pneumocytosis jiroveci (P. carinii) in adults and children.
2) Treatment and prophylaxis of toxoplasmosis, treatment of nocardiosis.
3) Treatment of urinary tract infections and acute exacerbations of chronic bronchitis, where there is bacterial evidence of sensitivity to Co-trimoxazole and a good reason to prefer this combination to a single antibiotic.
4) Treatment of acute otitis media where there is a good reason to prefer this combination.

CONTRAINDICATIONS

• Known hypersensitivity to trimethoprim, sulphonamides or any other excipient.
• Pregnancy – especially in the period prior to birth.
• Severe hepatic failure or marked liver parenchymal damage, jaundice.
• Serious haematological disorders and porphyria.
• Severe renal insufficiency where repeated measurements of the plasma concentration cannot be performed.
• Trimoksazol® should not be given to neonates during the first 6 weeks, except for the treatment/prophylaxis of Pneumocytosis jiroveci (P. carinii) in infants of four weeks of age or greater

PACKAGING

Box with 20 tablets of (400 mg+80 mg) (2 blisters x 10 tablets).
Box with a plastic bottle with childproof plastic cap, with 120 ml syrup of (200 mg+40 mg)/5 ml.